Correspondence 0001213900-24-111516 from Nok Therapeutics, Inc. (CIK 0002038166)
Nok Therapeutics, Inc. (CIK 0002038166)
Date: Dec. 23, 2024 · CIK: 0002038166 · Accession: 0001213900-24-111516
AI Filing Summary & Sentiment
File numbers found in text: 024-12511
Referenced dates: December 20, 2024
Letter
United States Securities and Exchange Commission Office of Life Sciences Re: NÖK Therapeutics, Inc. Amendment No. 5 to the Offering Statement on Form 1-A Filed December 16, 2024 File No. 024-12511
Dear Mses. Robertson and Dicker and Messrs. Edwards and Campbell,
We are in receipt of your comment letter dated December 20, 2024 in the above referenced matter and hereby respond to same as follows:
Amendment No. 5 to Offering Statement on Form 1-A
Use of Proceeds, page 18
1. We note your response to prior comment 4. Please describe the use of the proceeds arising from the indebtedness that will be discharged with the proceeds of this offering. Refer to Instruction 6 to Item 6 of Form 1-A.
RESPONSE: We have updated the Form 1-A/A accordingly.
Respectfully Submitted,
/s/ Robert Lewis
Show Raw Text
CORRESP
1
filename1.htm
NÖK THERAPEUTICS, INC.
1452 N. US HWY 1, Suite 123
Ormond Beach, FL 32174
December 23, 2024
Vanessa Robertson
Lynn Dicker
Chris Edwards
Alan Campbell
United States Securities and Exchange Commission
Office of Life Sciences
Washington, DC
Re:
NÖK Therapeutics, Inc.
Amendment No. 5 to the Offering Statement on Form 1-A
Filed December 16, 2024
File No. 024-12511
Dear Mses. Robertson and Dicker and Messrs. Edwards
and Campbell,
We are in receipt of your
comment letter dated December 20, 2024 in the above referenced matter and hereby respond to same as follows:
Amendment No. 5 to Offering Statement on Form 1-A
Use of Proceeds, page 18
1.
We note your response to prior comment 4. Please describe the use of the proceeds arising from the indebtedness that will be discharged with the proceeds of this offering. Refer to Instruction 6 to Item 6 of Form 1-A.
RESPONSE: We have updated the Form 1-A/A accordingly.
Respectfully Submitted,
/s/ Robert Lewis
Robert Lewis, President, Chief Executive Officer and Director